98%
921
2 minutes
20
Background Atherectomy has become the fastest growing catheter-based peripheral vascular intervention performed in the United States, and overuse has been linked to increased reimbursement, but the patterns of use have not been well characterized. Methods and Results We used Blue Cross Blue Shield of Michigan Preferred Provider Organization and Medicare fee-for-service professional claims data from the Michigan Value Collaborative for patients undergoing office-based laboratory atherectomy in 2019 to calculate provider-specific rates of atherectomy use, reimbursement, number of vessels treated, and number of atherectomies per patient. We also calculated the rate that each provider converted a new patient visit to an endovascular procedure within 90 days. Correlations between parameters were assessed with simple linear regression. Providers completing ≥20 office-based laboratory atherectomies and ≥20 new patient evaluations during the study period were included. A total of 59 providers performing 4060 office-based laboratory atherectomies were included. Median professional reimbursement per procedure was $4671.56 (interquartile range [IQR], $2403.09-$7723.19) from Blue Cross Blue Shield of Michigan and $14 854.49 (IQR, $9414.80-$18 816.33) from Medicare, whereas total professional reimbursement from both payers ranged from $2452 to $6 880 402 per year. Median 90-day conversion rate was 5.0% (IQR, 2.5%-10.0%), whereas the median provider-level average number of vessels treated per patient was 1.20 (IQR, 1.13-1.31) and the median provider-level average number of treatments per patient was 1.38 (IQR, 1.26-1.63). Total annual reimbursement for each provider was directly correlated with new patient-procedure conversion rate (=0.47; <0.001), mean number of vessels treated per patient (=0.31; <0.001), and mean number of treatments per patient (=0.33; <0.001). Conclusions A minority of providers perform most procedures and are reimbursed substantially more per procedure compared with most providers. Procedural conversion rate, number of vessels, and number of treatments per patient represent potential policy levers to curb overuse.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750064 | PMC |
http://dx.doi.org/10.1161/JAHA.121.023356 | DOI Listing |
J Voice
August 2025
Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium; Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, Paris Saclay University, Phonetics and Phonology Laboratory (UMR 7018 CNRS, Université Sorbon
Objective: To investigate the surgical and voice quality outcomes of office-based laryngeal surgery for patients with laryngeal dysplasia and leukoplakia.
Data Sources: PubMed, Google scholar, and Cochrane databases.
Review Methods: Three independent investigator search databases for studies reporting surgical or voice quality outcomes of patients treated with office-based surgery for vocal fold dysplasia or leukoplakia.
J Clin Hypertens (Greenwich)
August 2025
Grupo de Expertos en Hipertensión Arterial México (GREHTA), Ciudad de México, Mexico.
Arterial hypertension often coexists with comorbidities that increase vascular damage. Although the primary goal is to reduce cardiovascular risk, the available risk scores can produce varying estimates. Here, we aim to compare the prevalence of cardiovascular risk categories using three equations (Globorisk, SCORE2, and PREVENT) in adults living with arterial hypertension and to assess their association as stratification tools for end-organ damage (EOD).
View Article and Find Full Text PDFJ Am Coll Cardiol
July 2025
Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
J Vasc Surg
July 2025
Department of Surgery, Texas Christian University School of Medicine, Fort Worth, TX; University Vascular Associates, Los Angeles, CA; Dallas-Fort Worth Vascular Group, Dallas, TX. Electronic address:
Objective: This study evaluates the safety and efficacy of arterial closure devices (ACDs) used in arterial procedures between 2018 and 2023, comparing patient outcomes with data from 2012 to 2013. The primary objective was to assess changes in patient outcomes in a larger patient dataset after modifications in ACD use in clinical practice.
Methods: Data were retrospectively reviewed, covering femoral, radial, and pedal access cases performed by 15 providers.
J Dtsch Dermatol Ges
July 2025
Center for Chronic Pruritus and Section for Pruritus Medicine of the Department of Dermatology, Münster University Hospital, Münster, Germany.
Background And Objectives: Knowledge on patient care gaps of prurigo nodularis (PN) is limited. This retrospective chart review (ADVANCE PN) investigated unmet medical needs and gaps in diagnostics, treatment, and management of patients with PN in routine care in Germany.
Patients And Methods: Medical records for adults newly diagnosed with PN between January 2012 and December 2022 from dermatologic clinics and office-based dermatologists were analyzed.